Breast cancer risk in relation to different types of hormone replacement therapy in the E3N-EPIC cohort.
about
Bioidentical hormones for menopausal hormone therapy: variation on a themeIn vivo estrogenic comparisons of Trifolium pratense (red clover) Humulus lupulus (hops), and the pure compounds isoxanthohumol and 8-prenylnaringeninEstrogen and progestogen use in postmenopausal women: July 2008 position statement of The North American Menopause Society.Comparison of the in vitro estrogenic activities of compounds from hops (Humulus lupulus) and red clover (Trifolium pratense)Progestogens in menopausal hormone therapySteroid hormones, steroid receptors, and breast cancer stem cellsMolecular determinants of context-dependent progesterone receptor action in breast cancerBody mass index and breast cancer risk according to postmenopausal estrogen-progestin use and hormone receptor statusDeciphering the divergent roles of progestogens in breast cancer.Breast cancer risk associated with different HRT formulations: a register-based case-control study.Hormone replacement therapy use and plasma levels of sex hormones in the Norwegian Women and Cancer postgenome cohort - a cross-sectional analysis.Comparative actions of progesterone, medroxyprogesterone acetate, drospirenone and nestorone on breast cancer cell migration and invasion.Extra-nuclear signaling of progesterone receptor to breast cancer cell movement and invasion through the actin cytoskeleton.Estrogen Effects on the Mammary Gland in Early and Late Life and Breast Cancer RiskTreatment of the menopause: the swinging pendulum.Off-label use of hormones as an antiaging strategy: a reviewPersonal history of endometriosis and risk of cutaneous melanoma in a large prospective cohort of French womenGynaecologic challenging issues in the management of BRCA mutation carriers: oral contraceptives, prophylactic salpingo-oophorectomy and hormone replacement therapy.Bioidentical hormone micronized progesteroneProgestogens used in postmenopausal hormone therapy: differences in their pharmacological properties, intracellular actions, and clinical effectsProgesterone--promoter or inhibitor of breast cancer.Risk factors of breast cancer: a systematic review and meta-analysis.Tracking progesterone receptor-mediated actions in breast cancerProgestins and progesterone in hormone replacement therapy and the risk of breast cancer.New progestagens for contraceptive use.Hepcidin promotes osteogenic differentiation through the bone morphogenetic protein 2/small mothers against decapentaplegic and mitogen-activated protein kinase/P38 signaling pathways in mesenchymal stem cells.Unequal risks for breast cancer associated with different hormone replacement therapies: results from the E3N cohort studyIMS updated recommendations on postmenopausal hormone therapy.New products and regimens (since 2003).The bioidentical hormone debate: are bioidentical hormones (estradiol, estriol, and progesterone) safer or more efficacious than commonly used synthetic versions in hormone replacement therapy?Risk of breast cancer by type of menopausal hormone therapy: a case-control study among post-menopausal women in France.Hormonal therapy and risk of breast cancer in mexican women.Progesterone action in breast, uterine, and ovarian cancers.Postmenopausal hormone therapy and breast cancer risk: current status and unanswered questions.Changing concepts: Menopausal hormone therapy and breast cancer.Estimated numbers of postmenopausal women treated by hormone therapy in France.Serious psychiatric outcome of subjects prenatally exposed to diethylstilboestrol in the E3N cohort study.Previous oral contraceptive use and breast cancer risk according to hormone replacement therapy use among postmenopausal women.The discovery and mechanism of action of letrozole.Oral progestagens before menopause and breast cancer risk.
P2860
Q24643351-164A54AE-11B2-40FA-921F-35066B61A7DCQ24647204-CD520976-ADEF-423D-A4B0-5DCEFD464008Q24658109-944A076A-6C26-4B81-95FD-A32C9649F1D4Q24682645-880F4DDC-DF0F-44A4-8F58-EA307C9B72ACQ26795567-20EBA337-7E92-4BEA-AB45-28A273EE780AQ26799113-C3679B0B-2113-44CB-A23E-E4F5802596F7Q26997928-704B62B7-FF2B-46CF-A1E9-6492DBE41414Q27012792-A5884878-D849-4FEA-8734-AC8E9ED9A376Q30240711-88982E0D-CC5D-4C56-B73E-1E94577C2EB7Q33257142-F8137E8D-95B0-4A6E-A2C5-842B92DEA7DDQ33314618-8148B051-9AEE-4D10-8957-9BE446B39175Q33341492-651357DD-9065-4C8C-8038-6E7622D33819Q33355956-216A1A97-6745-48B5-B83F-541ED0F588EBQ33729336-92C47A1A-FD2B-4BAE-9A69-4128C0F3AB90Q33876807-8BE26D68-B821-4B87-9EBD-976D8AB71B58Q33976165-87F7D3EE-40C7-482A-B6E6-1412C55B6557Q34007748-CA019871-3CF2-4C26-B9B3-019E74955CF4Q34126089-F28B43DA-C439-4222-AFDE-E0AC3F5E6C22Q34292053-03B2D4A6-0DFD-4815-A4EA-593F876814B5Q34317537-CBD136FC-DE42-42AC-AEF8-15F0C8087B4EQ34323606-F4CA672C-7A60-483F-B76E-358F73536F3DQ34346863-E83F3E0B-A02D-41DE-AF56-C41DB3B37552Q34388848-8AC6B561-F830-4F59-A687-3791A2C34F07Q34420425-97E5A62E-D42D-4F10-99C6-871139AE2897Q34468158-6D76FBD2-7D0B-4AF9-AA17-9A8E2D10C5C2Q34540833-A74D8F5E-4508-4542-8E26-8A02882CD658Q34576753-B7E6A48F-D247-441E-9D03-7741350A2D2FQ34626471-84505BFF-A64C-4A14-BA07-10E7B02ED04BQ34691279-198AC865-462C-46D0-B075-236AAA5C374EQ34932849-3C241972-EC12-4D77-AD5C-9650EDD5669FQ35040736-EE9CEBCB-F1FE-41CD-B339-136E4F69E3E3Q35048651-F8B9AA1E-D7D7-4E3D-8F80-BA1808D3EC20Q35108906-D6D6D8D5-19C3-4A3E-BEFE-8C7EE884F83CQ35196707-E1A493B3-55E4-4D7A-B4D6-FEABEC101CC7Q35866374-CE01D470-928D-494F-B1E9-6C356E036865Q35987347-7E76EC9B-B2AF-4A3E-ABAD-5727A70DB34CQ35990186-F6A81DB4-F86C-477C-84AC-221501DDC360Q35990596-BF6FAF77-F518-433F-842C-CBEE49FE8CBAQ36026408-538B459A-D4FA-429F-B9EC-7837FB1811C3Q36113902-C5EEC2E5-D366-4009-A0B1-328172E18B1A
P2860
Breast cancer risk in relation to different types of hormone replacement therapy in the E3N-EPIC cohort.
description
2005 nî lūn-bûn
@nan
2005 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2005 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
name
Breast cancer risk in relation ...... herapy in the E3N-EPIC cohort.
@ast
Breast cancer risk in relation ...... herapy in the E3N-EPIC cohort.
@en
Breast cancer risk in relation ...... herapy in the E3N-EPIC cohort.
@nl
type
label
Breast cancer risk in relation ...... herapy in the E3N-EPIC cohort.
@ast
Breast cancer risk in relation ...... herapy in the E3N-EPIC cohort.
@en
Breast cancer risk in relation ...... herapy in the E3N-EPIC cohort.
@nl
prefLabel
Breast cancer risk in relation ...... herapy in the E3N-EPIC cohort.
@ast
Breast cancer risk in relation ...... herapy in the E3N-EPIC cohort.
@en
Breast cancer risk in relation ...... herapy in the E3N-EPIC cohort.
@nl
P50
P356
P1476
Breast cancer risk in relation ...... herapy in the E3N-EPIC cohort.
@en
P2093
Franco Berrino
Valérie Avenel
P304
P356
10.1002/IJC.20710
P577
2005-04-01T00:00:00Z